PEGylated single-walled carbon nanotubes as nanocarriers for cyclosporin A delivery

AAPS PharmSciTech

Volumn 14, Issue 2, 2013, Pages 593-600

  Hadidi, Naghmeh ^a   Kobarfard, Farzad ^a   Nafissi Varcheh, Nastaran ^a   Aboofazeli, Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

carbon nanotubes; cyclosporin A; drug loading; elemental analysis; functionalization

Indexed keywords

CYCLOSPORIN A; MACROGOL; NANOCARRIER; PHOSPHOLIPID; SINGLE WALLED NANOTUBE;

ARTICLE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; PRIORITY JOURNAL; SURFACE PROPERTY; ULTRAVIOLET SPECTROPHOTOMETRY;

CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG CARRIERS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; NANOTECHNOLOGY; NANOTUBES, CARBON; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SUCCINIC ANHYDRIDES; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84879080904     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9944-2     Document Type: Article

References (71)

1. Tang MF, Lei L, Guo SR, Huang WL. Recent progress in nanotechnology for cancer therapy. Chin J Cancer. 2010;29(9):775-80.
2. Mielcarek J, Skupin P. Functionalization of carbon nanotubes for multimodal drug delivery. Przegl Lek. 2011;68(3):167-70.
3. Ilbasmis-Tamer S, Degim IT. A feasible way to use carbon nanotubes to deliver drug molecules: transdermal application. Expert Opin Drug Deliv. 2012;9(8):991-9.
4. Klumpp C, Kostarelos K, Prato M, Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta Biomembr. 2006;1758(3):404-12.
5. Meng L, Zhang X, Lu Q, Fei Z, Dyson PJ. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumor. Biomaterials. 2012;33:1689-98.
6. Gomez-Gualdrón DA, Burgos JC, Yu J, Balbuena PB. Carbon nanotubes: engineering biomedical applications. Prog Mol Biol Transl Sci. 2011;104:175-245.
7. Foldvari M. Formulating nanomedicines: focus on carbon nanotubes as novel nanoexcipients. Key Eng Mater. 2010;441:53-74.
8. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomed Nanotechnol Biol Med. 2008;4(3):183-200.
9. Zhang Y, Bai Y, Yan B. Functionalized carbon nanotubes for potential biomedical application. Drug Deliv Today. 2010;15(11-12):428-35.
10. Endo M, Strano MS, Ajayan PM. Potential applications of carbon nanotubes. In: Jurio A, Dresselhaus G, Dresselhaus MS, editors. Carbon nanotubes advanced topics in the synthesis, structure, properties and applications. Berlin: Springer; 2008. p. 13-62.
11. Liang F, Chen B. A review on biomedical applications of single-walled carbon nanotubes. Curr Med Chem. 2010;17:10-24.
12. Andrews RJ. Nanotechnology and drug delivery: getting there is only half of the challenge! CNS Neurol Disord Drug Targets. 2012;11(1):96-7.
13. Boncel S, Müller KH, Skepper JN, Walczak KZ, Koziol KK. Tunable chemistry and morphology of multi-wall carbon nanotubes as a route to non-toxic, theranostic systems. Biomaterials. 2011;32(30):7677-86.
14. Bonner JC. Carbon nanotubes as delivery systems for respiratory disease: do the dangers outweigh the potential benefits? Expert Rev Respir Med. 2011;5(6):779-87.
15. Bottini M, Rosato N, Bottini N. PEG-modified carbon nanotubes in biomedicine: current status and challenges ahead. Biomacromolecules. 2011;12(10):3381-93.
16. Chen C, Xie XX, Zhou Q, Zhang FY, Wang QL, Liu YQ, et al. EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide. Nanotechnology. 2012;23(4):045104.
17. Coyuco JC, Liu Y, Tan BJ, Chiu GN. Functionalized carbon nanomaterials: exploring the interactions with Caco-2 cells for potential oral drug delivery. Int J Nanomed. 2011;6:2253-63.
18. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 2011;165(7-8):1628-51.
19. Gulati N, Gupta H. Two faces of carbon nanotube: toxicities and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 2012;29(1):65-88.
20. Ji Z, Lin G, Lu Q, Meng L, Shen X, Dong L, et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Colloid Interface Sci. 2012;365(1):143-9.
21. Karmakar A, Lancu C, Bartos DM, Mahmood MW, Ghosh A, Xu Y, et al. Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF-conjugated, single-walled carbon nanotubes. J Appl Toxicol. 2012;32(5):365-75.
22. Lay CL, Liu J, Liu Y. Functionalized carbon nanotubes for anticancer drug delivery. Expert Rev Med Devices. 2011;8(5):561-6.
23. Liu H, Hui X, Wang Y, He Z, Li S. Effect of intratumoral injection on the biodistribution and therapeutic potential of novel cremophor EL-modified single-walled nanotube loading doxorubicin. Drug Dev Ind Pharm. 2012;38(9):1031-8.
24. Lu YJ, Wei KC, Ma CC, Yang SY, Chen JP. Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B Biointerfaces. 2012;89:1-9.
25. Luo X, Matrang C, Tan S, Alba N, Cui XT. Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone. Biomaterials. 2013;2(26):6316-23.
26. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomed. 2011;6:2963-79.
27. Terzyk AP, Pacholczyk A, Winiewski M, Gauden PA. Enhanced adsorption of paracetamol on closed carbon nanotubes by formation of nanoaggregates: carbon nanotubes as potential materials in hot-melt drug deposition-experiment and simulation. J Colloid Interface Sci. 2012;376(1):209-16.
28. Wang Y, Xu H, Liu H, Wang Y, Sun J, He Z. Efficacy and biodistribution of tocopheryl polyethylene glycol succinate non-covalent functionalized single walled nanotubes loading doxorubicin in sarcoma bearing mouse model. J Biomed Nanotechnol. 2012;8(3):450-7.
29. Wang Y, Yang S-T, Wang Y, Liu Y, Wang H. Adsorption and desorption of doxorubicin on oxidized carbon nanotubes. Colloids Surf B: Biointerfaces. 2012;97:62-9.
30. Prakash S, Malhotra M, Shao W, Tomaro-Duchesneau C, Abbasi S. Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev. 2011;63(14-15):1340-51.
31. Liu Z, Tabakman S, Welsher K, Dai H. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2(2):85-120.
32. Pastorin G. Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option? Pharm Res. 2009;26(4):746-69.
33. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. J Am Chem Soc Nano. 2009;3(2):307-16.
34. Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, et al. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol. 2007;2(2):108-13.
35. Dumortier H, Lacotte S, Pastorin G, Marega R, Wu W, Bonifazi D, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006;6(7):1522-8.
36. Sayes CM, Liang F, Hudson JL, Mendez J, Guo WH, Beach JM, et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett. 2006;161:135-42.
37. Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol. 2009;4(10):627-33.
38. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 2008;41:60-8.
39. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol. 2005;9:674-9.
40. Li SS, He H, Jiao QC, Chuong PH. Applications of carbon nanotubes in drug and gene delivery. Prog Chem. 2008;20:1798-803.
41. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotube cell translocation and delivery of nucleic acids in vitro and in vivo. J Mater Chem. 2008;18:17-22.
42. Zhuang L, Robinson JT, Tabakman SM, Yanga K, Dai H. Carbon materials for drug delivery and cancer therapy. Mat Today. 2011;14(7-8):316-23.
43. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed. 2005;44(39):6358-62.
44. Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun. 2006;11:1182-4.
45. Feazell RP, Nakayama-Ratchford N, Dai H, Lippard S. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum (IV) anticancer drug design. J Am Chem Soc. 2007;129(27):8438-9.
46. Dhar S, Liu Z, Thomale J, Dai H, Lippard S. Targeted single-wall carbon nanotube-mediated Pt (IV) prodrug delivery using folate as a homing device. J Am Chem Soc. 2008;130(34):11467-76.
47. Bhirde AA, Patel S, Sousa AAA, Patel V, Molinolo AA, Ji Y, et al. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine. 2010;5(10):1535-46.
48. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68(16):6652-60.
49. Liu Z, Sun X, Nakayama N, Dai H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. J Am Chem Soc. 2007;1(1):50-6.
50. Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc. 2008;130(33):10876-7.
51. Ali-Boucetta H, Al-Jamal KT, McCarthy D, Prato M, Bianco A, Kostarelos K. Multi-walled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun. 2008;4:459-61.
52. Sun X, Liu Z, Welsher K, Robinson T, Goodwin A, Zarc S, et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res. 2008;1(3):203-12.
53. Kam NWS, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J Am Chem Soc. 2004;126:6850-1.
54. Kam NWS, Dai H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J Am Chem Soc. 2005;127(16):6021-606.
55. Madaeni SS, Derakhshandeh K, Ahmadi S, Vatanpour V, Zinadini S. Effect of modified multi-walled carbon nanotubes on release characteristics of indomethacin from symmetric membrane coated tablets. J Membr Sci. 2012;389:110-6.
56. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: I. pharmaceutical properties. Nanomedicine. 2008;4(3):173-82.
57. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A. 2006;103(9):3357-62.
58. Lacerda L, Herrero MA, Venner K, Bianco A, Prato M, Kostarelos K. Carbon nanotube shape and individualization critical for renal excretion. Small. 2008;4(8):1130-2.
59. Liu Z, Davis C, Cai W, He L, Chen X, Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A. 2008;105(5):1410-5.
60. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumor targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007;2:47-52.
61. Hadidi N, Kobarfard F, Nafissi-Varcheh N, Aboofazeli R. Optimization of single-walled carbon nanotube solubility by non-covalent PEGylation using experimental design methods. Int J Nanomed. 2011;6:737-46.
62. Hadidi N, Hosseini Shirazi SF, Kobarfard F, Nafissi-Varcheh N, Aboofazeli R. Evaluation of the effect of PEGylated single-walled carbon nanotubes on viability and proliferation of Jurkat cells. IJPR. 2011;11(1):27-37.
63. Son SJ, Bai X, Lee SB. Inorganic hollow nanoparticles and nanotubes in nanomedicine. I. Drug/gen delivery applications. Drug Discov Today. 2007;12(15-16):650-6.
64. Zakharian TY, Seryshev A, Sitharaman B, Gilbert BE, Knight V, Wilson LJ. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc. 2005;127(36):12508-9.
65. Kang B, Chang S, Dai Y, Yu D, Chen D. Cell response to carbon nanotubes: size-dependent intracellular uptake mechanism and subcellular fate. Small. 2010;6(21):2362-6.
66. Mu Q, Broughton DL, Yan B. Endosomal leakage and nuclear translocation of multiwalled carbon nanotubes: developing a model for cell uptake. Nano Lett. 2009;9(12):4370-5.
67. Moore M. Do nanoparticles present ecotoxicological risks for the health of the aquatic environment? Environ Int. 2006;32(8):967-76.
68. Zhou F, Xing D, Wu B, Wu S, Ou Z, Chen WR. New insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes. Nano Lett. 2010;10(5):1677-81.
69. Jin HD, Heller A, Strano MS. Single-particle tracking of endocytosis and exocytosis of single-walled carbon nanotubes in NIH-3T3 cells. Nano Lett. 2008;8(6):1577-85.
70. Beauchesne PR, Chung NSC, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33(3):211-20.
71. Pollard S, Nashan B, Johnston A, Hoyer P, Belitsky P, Keown P. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporine A. Clin Ther. 2003;25(6):1654-69.